139290-65-6
139290-65-6 結(jié)構(gòu)式
基本信息
諾和靈 M100907
VOLINANSERIN MDL 100907 (R構(gòu)型)
Volinanserin MDL 100907 (R構(gòu)型）
MDL100907
R-MDL 100907
VOLINANSERIN
MDL 100907 NEW
MDL100907-L-tartrate
MDL100907 tartrate salt
MDL 100907 (MDL-100907
MDL-100907(Volinanserin)
Volinanserin (MDL100907)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | HY-14940 | 139290-65-6 Volinanserin | 139290-65-6 | 5mg | 1100元 |
| 2024/11/08 | HY-14940 | 139290-65-6 Volinanserin | 139290-65-6 | 10mM * 1mLin DMSO | 1210元 |
| 2024/11/08 | HY-14940 | 139290-65-6 Volinanserin | 139290-65-6 | 10mg | 1760元 |
常見問題列表
| Target | Value |
|
5-HT2 receptor
(Cell-free assay) | 0.36 nM(Ki) |
Volinanserin (MDL 100907) is a potent antagonist at the 5-HT 2 receptor, with a K i of 0.36 nM, and shows 300-fold selectivity for 5-HT 2 receptor over 5-HT 1c receptor, alpha-1 and DA D 2 receptors. Volinanserin has antipsychotic activity.
Volinanserin (MDL 100907; 0.008-2.0 mg/kg, i.p.) significantly decreases d-amphetamine-stimulated locomotor activity in mice, with an ED 50 of 0.3 mg/kg, but shows no obvious reduction in the base-line locomotor activity in mice. Volinanserin produces atalepsy with an ED 50 of 10-50 mg/kg in rats. Volinanserin does not reduces apomorphine-induced stereotypies or produces catalepsy in rats. Volinanserin (M100907) combined with MK-801 significantly decreases reinforcers at 1 μg/kg, but dose-dependently (10, 100 μg/kg) antagonizes the disruptive effect of MK-801 in rats via i.p. administration. Volinanserin (6.25 μg/kg) enhances the antidepressant-like action of desipramine in rats performing under a DRL 72-s schedule, and elevates the antidepressant-like effect of tranylcypromine.